IgG antibody response against Nucleocapsid and Spike protein post SARS-CoV-2 infection

Hari Ram Choudhary
  ICMR - Regional Medical Research Centre, Bhubaneswar   https://orcid.org/0000-0001-6457-7202

Debaprasad Parai
  ICMR - Regional Medical Research Centre, Bhubaneswar   https://orcid.org/0000-0003-0266-5623

Girish Chandra Dash
  ICMR - Regional Medical Research Centre, Bhubaneswar   https://orcid.org/0000-0003-2771-5965

Annalisha Peter
  ICMR - Regional Medical Research Centre, Bhubaneswar   https://orcid.org/0000-0002-0590-0169

Subrat Kumar Sahoo
  ICMR - Regional Medical Research Centre, Bhubaneswar

Matrujyoti Pattnaik
  ICMR - Regional Medical Research Centre, Bhubaneswar

Usha Kiran Rout
  ICMR - Regional Medical Research Centre, Bhubaneswar

Rashmi Ranjan Nanda
  ICMR - Regional Medical Research Centre, Bhubaneswar

Sanghamitra Pati (✉ drsanghamitra12@gmail.com)
  ICMR - Regional Medical Research Centre, Bhubaneswar   https://orcid.org/0000-0002-7717-5592

Debdutta Bhattacharya (✉ drdebdutta.bhattacharya@yahoo.co.in)
  ICMR - Regional Medical Research Centre, Bhubaneswar   https://orcid.org/0000-0001-5199-5288

Short Report

Abstract

Objectives: Coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. Study of dynamicity and durability of naturally developed antibodies against SARS-CoV-2 are of great importance from an epidemiological viewpoint.

Methods: In this observational cohort study, we have followed up the 76 individuals who tested positive for SARS-CoV-2 infection by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) for 16 weeks (post enrollment) to record the periodic changes in titre, concentration, clinical growth and persistence of naturally developed SARS-CoV-2 antibodies. We collected serum samples from these individuals for 16 weeks with a frequency of weekly and fortnightly during each follow-up and tested them in two CLIA-based platforms (Abbott Architect i1000SR and Roche Cobas e411) for testing SARS-CoV-2 antibodies both qualitatively and quantitatively.

Results: We recorded the antibody magnitude of these individuals 10 times between September 2020 and February 2021. We found a waning of antibodies against nucleocapsid antigen protein but not a complete disappearance by the end of 16 weeks. Out of 76 cases, 30 cases (39.47%) became seronegative in qualitative assay, although all the sera samples (100%) remained positive when tested in quantitative assay.

Conclusion: The lower persistence of anti-nucleocapsid SARS-CoV-2 antibody may not be the exact phenomenon as those cases were still seropositive against spike protein and help in neutralizing the virus.

Introduction

Since its emergence in December 2019, from Wuhan city of China, SARS-CoV-2 virus has spread rapidly throughout the world. As of April 12, 2021, more than 135 million individuals were infected with SARS-CoV-2 and 2.92 million SARS-CoV-2-associated deaths were reported.[1] USA, India, and Brazil account for most of the cases worldwide with India recording about 13.52 million cases and 1.70 million deaths.[1,2]

In general, antibodies are known to play an important role in neutralizing the virus and provide protection to the host against re-infection. Antibodies to SARS-CoV-2 can target many of its encoded proteins, including structural and non-structural antigens. Thus far, two structural proteins have been used as target antigens for serological assays for SARS-CoV-2. One is the abundant nucleocapsid protein (N), second is the structural spike protein (S) often used as a target for characterizing the immune response to SARS-CoV-2. However, there is limited understanding of antibody responses and persistence post infection with SARS-CoV-2 virus.[3,4] Specifically, we lack detailed descriptions and precise estimates concerning the magnitude and duration of responses following the infection. Upon infection, SARS-CoV-2 elicits humoral responses, and within 3 weeks almost all infected patients develop antibodies against the receptor-binding domain (RBD) and the S1 and S2 domains of the spike glycoprotein, as well as against

the nucleocapsid protein.[5,6] It is known from other coronaviruses and it holds true for SARS-CoV-2 that the spike is the main, and potentially the only, target for neutralizing antibodies.[7] However in-depth knowledge on the magnitude, timing, and longevity of antibody responses after SARS-CoV-2 infection is vital for understanding the role of the antibodies in disease clearance and protection from reinfection and/or disease. Although some studies from Iceland and the USA demonstrated the persistence of antibodies SARS-CoV-2 infection beyond 4 months post infection, other studies have reported rapid waning of antibodies within 3–4 months.[7–9] The present study uses periodic samples from 76 individuals with RT-qPCR confirmed SARS-CoV-2 infection up to 16 weeks from enrolment into the study to understand the magnitude and durability of the antibody response.

Methods

Study setting

A cohort of 76 confirmed COVID-19 positive healthcare and frontline workers from Bhubaneswar city, India was included in this study. Individuals were enrolled into the cohort after 28 days of being tested positive by RT-qPCR for SARS-CoV-2 virus and were followed up for four months with a periodic sample collection. The study was approved by the Institutional Human Ethical Committee. Informed signed consent was obtained from individuals before their enrolment into the study.

Test Method

A 5 mL of blood sample was collected and serum was isolated to evaluate the IgG antibody against N and S-protein antigen. Antibody titre was determined by a commercial qualitative assay using Abbott architect i1000SR (Abbott Diagnostics, Chicago, USA) as per the manufacturer's instructions. The assay is a chemiluminescent microparticle immunoassay that detects IgG against the N protein of SARS-CoV-2. An index (S/C) of ≥ 1.4 was interpreted as reactive and < 1.4 index as non-reactive. The individals samples were tested for Ab against N protein were tested after 1st, 2nd, 3rd, 4th, 6th, 8th, 10th, 12th, 14th and 16th week of enrollment. The concentration of IgG antibody against RBD of SARS-CoV-2 S-protein in human was determined by Roche Cobas e411 (Roche Diagnostics GmbH, Mannheim, Germany) which is based on electrochemiluminescence technology for the quantitative detection of antibodies including IgG. A value of < 0.80 U/mL was considered as negative and values ≥ 0.8 U/mL were identified as positive. The individals samples were tested for Ab against spike protein after 1st, 4th, 10th and 16th week of enrollment. At least two consecutive positive samples were tested to classify a participant as seropositive, whereas disappearance of IgG was defined as having at least two negative tests after having been classified as seropositive.

Statistical analysis

SPSS software (IBM SPSS Statistics for Windows, version 24.0, Armonk, NY) and GraphPad Prism 7.00 for Windows (GraphPad Software, La Jolla, California, USA) were used for descriptive statistical analyses. *P*-values < 0.05 was considered as significant.

Result

SARS-CoV-2 antibody titres were periodically (10 times) measured in 76 individuals (healthcare and frontline workers) who were COVID-19 positive by RT-PCR. All the 76 study participants had anti-SARS-CoV-2 antibodies detected at enrolment and the median number of days between confirmation of RT-qPCR positive and serum antibody detection was 24 days. Mean antibody titre was measured as 4.49 index (SD ± 2.18 index) at week 1 which was started to wane from week 4 and decreased to 2.43 index (SD ± 2.11 index) at the end of week 16 in qualitative test detecting antibody against N-protein (Fig. 1A). In this cohort, participants from 18 to 63 years were categorized in four different age groups of 18–29 years (n = 31; 34.21%), 30–49 years (n = 19; 25%), 50 years and above (n = 19; 25%). The mean age of the participants was 36.5 years (SD ± 13.39) with 51 (67.11%) males and 25 (32.89%) were female. Among 76 participants, 60 (78.95%) were symptomatic during two weeks of the symptom onset (Table 1). The most common symptom found was fatigue (n = 58; 76.3%) followed by fever (n = 48; 63.1%) and cold (n = 46; 60.5%) (Figure S1). Forty-six participants (60.53%) were found to have a reactive level of antibody till 16 weeks, whereas 30 (39.47%) become seronegative against the N-protein of SARS-CoV-2 (Fig. 1A). Seventeen of those seronegative 30 individuals (56.67%) were aged between 18–29 years; 8 (26.67%) were aged between 30–49 years and 5 (16.67%) were 50 years or older. All the participants (100%) were found positive in quantitative antibody testing at 16 weeks in comparison to 46 (60.52%) in qualitative testing. The mean concentration of IgG antibody agaist S-protein were recorded as 141.28 U/ml, 174.84 U/ml, 241.27 U/ml and 356.69 U/ml at week 1, week 4, week 10 and week 16 respectively. An statistically significant increment in the mean antibody concentration was quantified at 16 weeks (356.69 U/ml ± 436.41 U/ml) compared to the first week (141.28 U/ml ± 166.07 U/ml) for antibody against S-protein (Fig. 1B).

Table 1
Follow up participants with confirmed positive for SARS-CoV-2 antibodies.

		All (n = 76)	Positive for antibodies after 16 weeks of follow up (n = 46)	Negative for antibodies after 16 weeks of follow up (n = 30)	P value
Age (in years)		36.5 (13.39, 18−63)	40.80 (12.76, 18−62)	34.33 (13.60, 19−63)	0.039*
Age by category (in years)	18−29	31 (40.79%)	14 (44.33%)	17 (56.67%)	0.072
	30−49	26 (34.21%)	18 (63.33%)	8 (26.67%)	
	50 & above	19 (25%)	14 (83.33%)	5 (16.67%)	
Gender	Male	51 (67.11%)	30 (58.82%)	21 (41.18%)	0.664
	Female	25 (32.89%)	16 (64%)	9 (36%)	
Infection history	Symptomatic	60 (78.95%)	39 (65%)	21 (35%)	0.122
	Asymptomatic	16 (21.05%)	7 (43.75%)	9 (56.25%)	

*t-test significant at $p < 0.05$ at 95% Confidence Interval

Discussion

The development of antibody is a common immunological phenomenon constantly happening in our body to give us protection, particularly against the newly invaded immunogens. In the case of COVID-19 infection, the antibody can be detected as soon as the first week from the onset of the symptoms depending on the patients' immune system.[10] Several studies are ongoing around the world to track down the durability of anti-SARS-CoV-2 IgG. Some studies have shown that IgG waning is quite fast in COVID-19 although no such study has been done with the Indian population to our best knowledge.[9,11]

In this study, 60 (78.95%) individuals were reported to be symptomatic which was contrasting with the study in the general distribution of covid positive cases where it was found to be 91% of asymptomatic SARS-CoV-2 positive cases.[12] The present study found around 40% of the serum samples were negative for IgG against N-protein at the end of 4 months, whereas a similar study in USA found only 7.7% SARS-CoV-2 IgG negative after 3−6 months following symptom onset.[13] The males were having higher titre values than females in both qualitative and quantitative testing at the end of 16 weeks although the

difference was statistically insignificant. Four (5.26%) of these individuals were hospitalised during the infection period and had developed a high antibody titre and the average was 7.22 index.

Our study showed a considerable difference in the result interpretation between qualitative and quantitative serological assays for COVID-19. In the qualitative assay, antibodies against SARS-CoV-2 was obsereved to persist for more than 16 weeks with a reduction in antibody levels which can be corroborated by a similar finding from Hubei province.[14] However, all the sera samples from 76 individuals were found to be positive in the quantitative assay platform against S protein of SARS-CoV-2. The 30 seronegative samples (mean antibody titre = 0.830 ± 0.306) detected in qualitative assay against N protein gave a mean concentration of 404.63 U/mL (± 380.91 U/mL) after 16 weeks. The threshold levels of serum antibody which could prevent re-infection of SARS-CoV-2 is still unknown and needs further research. Moreover, we found a gradual decline in qualitative antibody titre value in 55% of individuals after 16 weeks when compared to week 1. In the quantitative assay for the same samples, a time-dependent increment of antibody concentration was observed. However, the adaptive humoral immune response against SARS-CoV-2 S-protein may not give the full proof immunoprotection and could be limited as speculation as we don't know the threshold magnitude. We hypothesised that the anomaly between these two assays inference may be for the different target antigen as mentioned in the methodology. We also observed that asymptomatic individuals produced less titre of the antibody as found both in the qualitative and quantitative assay.

In conclusion, these data imply that antibody titre against N antigen protein is waning with time but not completely disappearing. However, the seronegative cases found against N-protein might not be the true negative as those were tested positive for antibody against S-protein antigen which would help in neutralizing the virus. Based on the study findings we recommend to test the presence of antibody against S-protein antigen to confer a final conclusive remark upon the persistence of SARS-CoV-2 antibody in an individual.

Declarations

Ethics approval and consent to participate

The study was ethically approved by the institutional human ethical committee of ICMR – Regional Medical Research Centre, Bhubaneswar.

Declaration of Competing Interest

The authors have no competing interests in any form.

Acknowledgement

References

1. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int. Accessed 12 April 2021.

2. Ministry of Health and Family Welfare, Government of India (COVID-19) Dashboard. Available at: https://main.mohfw.gov.in. Accessed 12 April 2021.

3. Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol 2020; 20:392–4.

4. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat Commun 2020; 11:4704.

5. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020; 5:eabe0367.

6. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity 2020; 52:910–41.

7. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370:1227–30.

8. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383:1724–34.

9. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020; 383:1085–7.

10. Lau EHY, Tsang OTY, Hui, DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2020; 12:63.

11. Bruni M, Cecatiello V, Diaz-Basabe A, et al. Persistence of Anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers. J Clin Med 2020; 9:3188.

12. Kumar N, Hameed SK, Babu GR, et al. Descriptive epidemiology of SARS-CoV-2 infection in Karnataka state, South India: Transmission dynamics of symptomatic vs. asymptomatic infections. EClinicalMedicine 2021; 32:100717.

13. Maine GN, Lao KM, Krishnan SM, et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol 2020; 133:104663.

14. Zhang X, Lu S, Li H, et al. Viral and antibody kinetics of COVID-19 patients with different disease severities in acute and convalescent phases: A 6-Month follow-up study. Virol Sin 2020; 35:820–9.

Figures

Figure 1

Periodic changes of anti-nucleocapsid SARS-CoV-2 antibody titre value (A). Comparison of anti-spike SARS-CoV-2 antibody concentration at week1, wee4, week10 and week16 (B). p<0.05 was considered as statistically significant.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FigureS1.docx